8-K: CervoMed's Phase 2b Trial for Dementia Drug Fails to Meet Endpoints, Pauses Phase 3 Preparations

CervoMed's RewinD-LB Phase 2b clinical trial for neflamapimod in dementia with Lewy bodies did not meet its primary or secondary endpoints, leading to a pause in Phase 3 trial preparations.

Summary

• CervoMed announced topline data from its RewinD-LB Phase 2b clinical trial for neflamapimod in patients with dementia with Lewy bodies (DLB).
• The trial did not achieve statistical significance for its primary endpoint, which was the change in the Clinical Dementia Rating Sum of Boxes (CDR-SB).
• Key secondary endpoints, including the Timed Up and Go (TUG) test, a Neuropsychological Test Battery (NTD), and the Clinicians Global Impression of Change (CGIC), also did not meet statistical significance.
• Initial analysis suggests that target plasma drug concentrations were not reached during the 16-week double-blind phase, potentially impacting the results.
• The company is pausing preparations for a planned Phase 3 trial in early-stage DLB until a full analysis of the data is complete.
• Neflamapimod showed a favorable safety and tolerability profile, consistent with previous studies, with no new safety signals identified.
• The full data set from the double-blind phase is expected in January 2025, and data from the open-label extension's first 16 weeks is expected in the late second quarter of 2025.
• The RewinD-LB trial was funded by a $21.3 million grant from the National Institutes of Health's National Institute on Aging.

Sentiment

Score: 3

Explanation: The document reports negative clinical trial results, a pause in Phase 3 preparations, and lower than expected drug concentrations, indicating a negative outlook for the company's drug development program.

Positives

• Neflamapimod demonstrated a favorable safety and tolerability profile, consistent with prior studies.
• No new safety signals were identified during the trial.
• The trial was funded by a $21.3 million grant from the National Institutes of Health.

Negatives

• The RewinD-LB Phase 2b trial did not meet its primary endpoint of change in CDR-SB.
• The trial also failed to meet key secondary endpoints.
• Target plasma drug concentrations were not achieved during the double-blind phase.
• Preparations for the Phase 3 trial in early-stage DLB have been paused.

Risks

• The failure to meet primary and secondary endpoints in the Phase 2b trial raises concerns about the efficacy of neflamapimod.
• Lower-than-expected plasma drug concentrations may indicate issues with drug delivery or dosage.
• The pause in Phase 3 trial preparations could delay the development timeline for neflamapimod.
• There is a risk that further analysis may not yield a viable path forward for the drug.
• The company's future success is dependent on the results of ongoing investigations and future trials.

Future Outlook

The company will thoroughly analyze the clinical and pharmacokinetic data from the trial to better understand its outcome and potential future development paths for the drug. This includes data expected to be available in the first half of 2025 from the first 16 weeks of the open label extension trial. The company is pausing all preparations for its previously planned Phase 3 trial in early-stage DLB until the full analysis is complete.

Management Comments

• We are disappointed with these results, particularly given our prior clinical experience with neflamapimod in patients with early-stage DLB and we are investigating the reasons for the lower-than-expected plasma drug concentrations, said John Alam, MD, Chief Executive Officer of CervoMed.
• We continue to believe neflamapimod may have potential as a treatment for DLB, and we will thoroughly analyze the clinical and pharmacokinetic data from the trial to better understand its outcome and potential future development paths for the drug, said John Alam, MD, Chief Executive Officer of CervoMed.
• We are grateful to the entire DLB community, including trial participants, their caregivers and families, and all of our investigators, sites and coordinators, said Kelly Blackburn, CervoMeds SVP of Clinical Development.

Industry Context

The failure of CervoMed's Phase 2b trial highlights the challenges in developing effective treatments for dementia with Lewy bodies, a disease with limited treatment options and a high unmet medical need. The company's focus on early-stage DLB patients is consistent with the industry's trend towards earlier intervention in neurodegenerative diseases.

Comparison to Industry Standards

• The failure of the RewinD-LB trial to meet its primary endpoint is a setback compared to some other clinical trials in neurodegenerative diseases that have shown positive results.
• For example, some trials for Alzheimer's disease have shown positive results in slowing cognitive decline, although these are not directly comparable to DLB.
• The lack of approved treatments for DLB makes it difficult to benchmark CervoMed's results against established standards, but the failure to achieve statistical significance is a negative outcome compared to the goals of most clinical trials.
• Other companies such as Biogen and Eisai have had some success with treatments for Alzheimer's, but DLB remains a more challenging area with fewer successful trials.

Stakeholder Impact

• Shareholders may experience a negative impact due to the trial's failure and the pause in Phase 3 preparations.
• Patients with DLB and their families may be disappointed by the lack of positive results.
• Employees may face uncertainty regarding the future of the company's drug development program.
• Investors may be less inclined to invest in the company due to the negative trial results.

Next Steps

• The company will analyze the full data set from the double-blind phase of the RewinD-LB trial, expected in January 2025.
• The company will analyze data from the first 16 weeks of the open-label extension portion of the trial, expected in the late second quarter of 2025.
• The company will investigate the reasons for the lower-than-expected plasma drug concentrations.
• The company will determine potential future development paths for the drug based on the analysis.
• The company will announce the timing of any presentation of additional data from the RewinD-LB trial at a later date.

Key Dates

Keywords

neflamapimod, dementia with Lewy bodies, DLB, clinical trial, Phase 2b, RewinD-LB, drug development, neurologic disorders, CDR-SB, clinical endpoints